Market Overview

UPDATE: Jefferies Raises PT to $18 on ARIAD Pharmaceuticals; Regulatory Catalysts

Related ARIA
GNC, Southern Copper And Others Insiders Have Been Buying
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel

Jefferies raises its price target from $17 to $18 on Buy-rated ARIAD Pharmaceuticals (NASDAQ: ARIA) on regulatory catalysts, despite a wider Q loss.

Jefferies notes, "Wider 1Q net loss of $56M (vs. our est of $39M) largely due to non-cash charge related to warrant liability revaluation. Despite higher OpEx expected in 2012, cash at end-1Q12 of $288M should be sufficient thru 1H13. With regulatory catalysts within next 12 months (ponatinib NDA filing in 3Q12/potential FDA approval early-2013), we believe ARIA is well positioned for meaningful upside."

ARIA closed at $15.91 on Wednesday.

Latest Ratings for ARIA

Aug 2014CitigroupMaintainsSell
Aug 2014JMP SecuritiesMaintainsMarket Outperform
Jun 2014UBSMaintainsNeutral

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings


Related Articles (ARIA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional